Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy

Christine Chan, Thomas Schiano, Eliana Agudelo, John Paul Haydek, Maarouf Hoteit, Marcela P. Laurito, John P. Norvell, Norah Terrault, Elizabeth C. Verna, Amy Yang, Josh Levitsky*

*Corresponding author for this work

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Interferon treatment of hepatitis C virus (HCV) infection after liver transplantation (LT) can result in immune-mediated graft dysfunction (IGD). The occurrence of, risk factors for, and outcomes of IGD with direct-acting antiviral (DAA) therapy have not been reported. We conducted a multicenter study of HCV+LT recipients who did or did not develop DAA-IGD (1 case: 2 controls—33 vs 66). Among all treated between 2014 and 2016, DAA-IGD occurred in 3.4% (33/978). IGD occurred only after treatment completion (76.0 [IQR, 47.0;176]). Among those treated, 48% had plasma cell hepatitis, 36% acute cellular rejection, 6% chronic rejection, and 9% combined findings. Median time to liver enzyme resolution was 77.5 days (IQR, 31.5;126). After diagnosis, hospitalizations, steroid-induced hyperglycemia, and infection occurred in a higher percentage of cases vs controls (33% vs 7.5%, 21% vs 1.5%, 9% vs 0%; all P <.05). Only one IGD patient died and none required retransplant. A multivariate regression analysis found that liver enzyme elevations during and soon after DAA therapy completion correlated with subsequent IGD. In conclusion, while DAA-IGD is uncommon, liver enzyme elevations during or after DAA therapy may be a sign of impending IGD. These indicators should guide clinicians to diagnose and treat IGD early before the more deleterious later clinical presentation.

Original languageEnglish (US)
Pages (from-to)2506-2512
Number of pages7
JournalAmerican Journal of Transplantation
Volume18
Issue number10
DOIs
StatePublished - Oct 2018

Keywords

  • antibiotic: antiviral
  • clinical research/practice
  • immunosuppression/ immune modulation
  • infection and infectious agents—viral: hepatitis C
  • infectious disease
  • liver allograft function/dysfunction
  • liver disease: infectious
  • liver transplantation/hepatology
  • rejection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy'. Together they form a unique fingerprint.

  • Cite this

    Chan, C., Schiano, T., Agudelo, E., Paul Haydek, J., Hoteit, M., Laurito, M. P., Norvell, J. P., Terrault, N., Verna, E. C., Yang, A., & Levitsky, J. (2018). Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy. American Journal of Transplantation, 18(10), 2506-2512. https://doi.org/10.1111/ajt.15053